Brian D Weiss MD

Pediatric Hematology & Oncology•Indianapolis, IN

Pediatric Solid Tumor Oncology

Nora Letzter Professor of Pediatrics Chief, Division of Pediatric Hematology/Oncology/Stem Cell Transplant Indiana University School of Medicine Riley Hospital for Children

Join to View Full Profile

Riley Hospital for Children705 Riley Hospital DrIndianapolis, IN 46202
Phone+1 317-944-8784

Education & Training

University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of California (San Francisco)Chief Residency, Pediatrics, 1996 - 1997
University of California (San Francisco)Residency, Pediatrics, 1993 - 1996
Northwestern University The Feinberg School of MedicineClass of 1993

Certifications & Licensure

IN State Medical License 2021 - 2025
OH State Medical License 2003 - 2025
KY State Medical License 2021 - 2024
CA State Medical License 1995 - 2005
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Start of enrollment: 2008 Apr 01
Completed
Phase 2
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
ACTIVE_NOT_RECRUITING
PHASE1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
ACTIVE_NOT_RECRUITING
PHASE1
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2013 Aug 28
Completed
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
COMPLETED
PHASE1
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
ACTIVE_NOT_RECRUITING
PHASE2
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
ACTIVE_NOT_RECRUITING
PHASE2
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Start of enrollment: 2020 Jun 11
ACTIVE_NOT_RECRUITING
PHASE1
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Start of enrollment: 2022 Aug 31
ACTIVE_NOT_RECRUITING
PHASE2
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma Start of enrollment: 2021 Nov 18
COMPLETED
PHASE3
Roles: Contact
Expanded Access Protocol Using 131I-MIBG
Available
Join now to see all

Publications & Presentations

PubMed

1 citations
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
Eva Dombi, Andrea M Gross, Brigitte C Widemann, Brian D Weiss, Scott R Plotkin
Journal of Clinical Oncology. 2025-03-19
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neurob...
Steven G DuBois, Chitose Ogawa, Lucas Moreno, Yaël P Mossé, Matthias Fischer
Cancer. 2025-02-15
Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report.
Puja J Umaretiya, Arlene Naranjo, Fan F Zhang, Julie R Park, Brian D Weiss
JAMA Network Open. 2025-02-03

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Pediatric Hematology Oncology-ASPHO
Member